Revisiting the monoamine hypothesis of depression: A new perspective

Perspectives in Medicinal Chemistry

Volumn , Issue 6, 2014, Pages

  Goldberg, Joel S ^a   Bell Jr , Clifton E ^b   Pollard, David A ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WINSTON SALEM STATE UNIVERSITY   (United States)

Author keywords

Depression; GABA; Monoamine oxidase

Indexed keywords

4 AMINOBUTYRIC ACID; ALIPHATIC AMINE; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOLAMINE; INDOLEAMINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE;

ARTICLE; CEREBROSPINAL FLUID; DEAMINATION; DEPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTHESIS; ISOELECTRIC POINT; LIPOPHILICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PH; REFRACTORY DEPRESSION; SPECTROPHOTOMETRY;

EID: 84899585540     PISSN: None     EISSN: 1177391X     Source Type: Journal    
DOI: 10.4137/PMc.s11375     Document Type: Article

References (21)

1. Freis ED. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med. 1954;251(25):1006-1008.
2. Kugaya A, Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr. 2005;10(10):808-819.
3. Sanacora G, Gueorguieva R, Epperson CN, et al. Subtype-specific alterations of gamma-amino butyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61(7):705-713.
4. Rattan AK, Dhatt RK, Mangat HK. Qualitative and quantitative changes in monoamine oxidase activity after acute third ventricle treatment of GABA, muscimol, and picrotoxin in rat. Gegenbaurs Morphol Jahrb. 1989;135(2): 357-365.
5. Price RB, Shungu DC, Mao X, et al. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry. 2009;65(9):792-800.
6. Hasler G, van der Veen J W, Tumonis T, et al. Reduced prefrontal glutamate/ glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64(2):193-200.
7. Todd KG, Baker GB. GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, deprenyl and clorgyline. J Afect Disord. 1995;35(3):125-129.
8. Todd KG, Baker GB. Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: a comparison with vigabatrin. J Pharm Pharm Sci. 2008;11(2):14s-21s.
9. Yu PH. Deamination of aliphatic amines of different chain lengths by rat liver monoamine oxidase A and B. J Pharm Pharmacol. 1989;41(3): 205-208.
10. Tenne M, Youdim MB, Ulitzur S, Finberg JP. Deamination of aliphatic amines by monoamine oxidase A and B studied using a bioluminescence technique. J Neurochem. 1985;44(5):1373-1377.
11. Greenstein JP, Winitz M. Chemistry of the Amino Acids. Vol 1. New York: John Wiley & Sons; 1961.
12. Goldberg JS. Selected gamma aminobutyric acid (GABA) esters may provide analgesia for some central pain conditions. Perspect Medicin Chem. 2010;4: 23-31.
13. Mazak K, Kokosi J, Noszal B. Lipophilicity of zwitterions and related species: a new insight. Eur J Pharm Sci. 2011;44(1-2):68-73.
14. Frieling H, Bleich S. Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006;256(5):268-273.
15. Saravana Babu C, Kesavanarayanan KS, Kalaivani P, Ranju V, Ramanathan M. A simple densitometric method for the quantification of inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in rat brain tissue. Chromatogr Res Int. 2011;2011:1-5.
16. Cuijpers P, van Straten A, Warmerdam L, Andersson G. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Depress Anxiety. 2009;26(3):279-288.
17. Feinberg SS. Combining stimulants with monoamine oxides inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry. 2004;65(11):1520-1524.
18. Flockhart DA. Dietary restrictions and drug interactions with monoamine oxi-dase inhibitors: an update. J Clin Psychiatry. 2012;73(suppl 1):17-24.
19. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95(4):434-441.
20. Keltner N, Harris CP. Serotonin syndrome: a case of fatal SSRI/MAOI interaction. Perspect Psychiatr Care. 1994;30(4):26-31.
21. Fawcett J, Kravitz HM, Zajecka JM, Schaf MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychop-harmacol. 1991;11(2):127-132.